Denali's treatment corrects for a lack of an enzyme produced by iduronate-2-sufatase gene, which is mutated in Hunter syndrome patients.

M.D., Chief Medical Officer of Denali. "This regulatory milestone brings us closer to our goal of delivering a new treatment option to the Hunter syndrome community as we continue to listen ...